Literature DB >> 4387221

Effect of inoculum size on in vitro susceptibility testing with lincomycin.

S Shadomy, J L Bruce, M M Kannan.   

Abstract

There is disagreement in the literature as to whether lincomycin is primarily a bacteriostatic or a bactericidal agent against gram-positive cocci and also regarding the levels of activity of this agent against susceptible microorganisms. These questions were examined in a study of the effect of inoculum size on the results of tube dilution susceptibility determinations with lincomycin against 49 clinical isolates of Staphylococcus aureus and 25 strains of streptococci and pneumococci. Lincomycin was both highly active and bactericidal when tested against 40 strains of S. aureus with inocula containing a maximum of 10(4) cells per ml [median minimal inhibitory concentration (MIC), 0.78 mug/ml; median minimal bactericidal concentration (MBC), 1.56 mug/ml]. With inocula of 10(5) cells per ml, lincomycin was primarily bacteriostatic (median MIC, 1.56 mug/ml; median MBC, 12.5 mug/ml). There were further decreases in inhibitory levels and significant losses of bactericidal activity when inocula containing more than 10(7) cells were tested (median MIC, 3.13 mug/ml; median MBC > 100 mug/ml). Similar measurements with streptococci and pneumococci revealed a lesser effect of inoculum size. The mean MBC value for alpha-hemolytic streptococci increased from 0.40 to 1.05 mug/ml with an increase in inocula from 10(4) to 10(6) cells per ml, but without a marked increase in MIC values. Similar results were obtained for beta-hemolytic streptococci and pneumococci.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4387221      PMCID: PMC547736          DOI: 10.1128/am.16.11.1663-1668.1968

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  7 in total

1.  THE SUSCEPTIBILITY OF CERTAIN BACTERIA TO LINCOMYCIN AS RELATED TO ATTAINABLE SERUM LEVELS IN HUMAN ADULTS.

Authors:  W E CLAPPER; G H MEADE; D B STEWART
Journal:  Am J Med Sci       Date:  1964-03       Impact factor: 2.378

2.  CLINICAL AND LABORATORY EXPERIENCE WITH LINCOMYCIN.

Authors:  G K DAIKOS; P KONTOMICHALOU; N PAPADOYANNAKIS; A TOURKANTONIS
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1963

3.  LINCOMYCIN: A CLINICAL STUDY.

Authors:  W J HOLLOWAY; R A KAHLBAUGH; E G SCOTT
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1963

4.  MICROBIOLOGICAL, PHARMACOLOGICAL AND CLINICAL STUDIES OF LINCOMYCIN.

Authors:  K KAPLAN; W H CHEW; L WEINSTEIN
Journal:  Am J Med Sci       Date:  1965-08       Impact factor: 2.378

Review 5.  Lincomycin.

Authors:  K Kaplan; L Weinstein
Journal:  Pediatr Clin North Am       Date:  1968-02       Impact factor: 3.278

6.  Lincomycin: activity in vitro and absorption and excretion in normal young men.

Authors:  C E McCall; N H Steigbigel; M Finland
Journal:  Am J Med Sci       Date:  1967-08       Impact factor: 2.378

7.  Action of lincomycin on staphylococci.

Authors:  M Bals; M Bratu
Journal:  Appl Microbiol       Date:  1966-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.